sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks E7820

E7820

CAS No.:
289483-69-8
Catalog Number:
AG002X5N
Molecular Formula:
C17H12N4O2S
Molecular Weight:
336.3678
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
≥98%
1 week
United States
$97
- +
10mg
≥98%
1 week
United States
$133
- +
50mg
≥98%
1 week
United States
$379
- +
100mg
≥98%
1 week
United States
$661
- +
Product Description
Catalog Number:
AG002X5N
Chemical Name:
E7820
CAS Number:
289483-69-8
Molecular Formula:
C17H12N4O2S
Molecular Weight:
336.3678
MDL Number:
MFCD09833234
IUPAC Name:
3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide
InChI:
InChI=1S/C17H12N4O2S/c1-11-5-6-15(17-16(11)13(9-19)10-20-17)21-24(22,23)14-4-2-3-12(7-14)8-18/h2-7,10,20-21H,1H3
InChI Key:
LWGUASZLXHYWIV-UHFFFAOYSA-N
SMILES:
N#Cc1cccc(c1)S(=O)(=O)Nc1ccc(c2c1[nH]cc2C#N)C
UNII:
TVH5K7949N
NSC Number:
719239
Properties
Complexity:
668  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
336.068g/mol
Formal Charge:
0
Heavy Atom Count:
24  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
336.369g/mol
Monoisotopic Mass:
336.068g/mol
Rotatable Bond Count:
3  
Topological Polar Surface Area:
118A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.4  
Literature
Title Journal
Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies. The AAPS journal 20110601
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research 20110101
Small molecule integrin antagonists in cancer therapy. Mini reviews in medicinal chemistry 20091001
Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820. Investigational new drugs 20090401
Integrins: molecular targets in cancer therapy. Current oncology reports 20060301
An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker. Clinical cancer research : an official journal of the American Association for Cancer Research 20040215
Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer research 20021101
Properties